

ADDENDUM

Helicobacter pylori and gut microbiota modulate energy homeostasis prior to inducing histopathological changes in mice

Yalda Khosravi^a, Ralph M Bunte^b, Kher Hsin Chiow^c, Tuan Lin Tan^c, Whye Yen Wong^c, Qian Hui Poh^c, Ignatius Mario Doli Sentosa^c, Shih Wee Seow^d, Arlaine Anne Amoyo^d, Sven Pettersson^{d,e,f}, Mun Fai Loke^a, and Jamuna Vadivelu^a

^aDepartment of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; ^bDuke-NUS Graduate Medical School, Singapore; ^cSchool of Chemical and Life Sciences, Singapore Polytechnic, Singapore; ^dNational Cancer Center, Singapore; ^eDepartment of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Stockholm, Sweden; ^fLKC School of Medicine, Nanyang Technological University, Singapore

ABSTRACT

Helicobacter pylori have been shown to influence physiological regulation of metabolic hormones involved in food intake, energy expenditure and body mass. It has been proposed that inducing *H. pylori*-induced gastric atrophy damages hormone-producing endocrine cells localized in gastric mucosal layers and therefore alter their concentrations. In a recent study, we provided additional proof in mice under controlled conditions that *H. pylori* and gut microbiota indeed affects circulating metabolic gut hormones and energy homeostasis. In this addendum, we presented data from follow-up investigations that demonstrated *H. pylori* and gut microbiota-associated modulation of metabolic gut hormones was independent and precedes *H. pylori*-induced histopathological changes in the gut of *H. pylori*-infected mice. Thus, *H. pylori*-associated argumentation of energy homeostasis is not caused by injury to endocrine cells in gastric mucosa.

ARTICLE HISTORY

Received 19 August 2015
Revised 5 November 2015
Accepted 9 November 2015

KEYWORDS

cross-talk; germ-free mice; *H. pylori*; microbiota; specific pathogen-free mice

Introduction

The human gastrointestinal (GI) tract consists of an upper (mouth, esophagus, stomach, duodenum, jejunum and ileum) and a lower part (cecum, colon, rectum and anus).^{1,2} It has one of the most complex microbial ecosystems.³ Composition of GI microbiota can be modified by physiological changes, such as aging⁴ and pregnancy.⁵ Several factors that can contribute to these modifications include: immunological or infectious diseases,⁶ antibiotic treatment and metabolites. Furthermore, the GI microbiota is involved in diverse normal host functions, including energy harvest and storage from the diet⁴ development and regulation of the gut-associated mucosal immune system,⁶ regulation of the central nervous system modulating brain development and behavior,⁷ protection against colonization by pathogens⁸ and detoxification of xenobiotics and carcinogens.

Unlike the oral cavity, stomach and colon, a few studies have suggested that the esophagus, is either

sterile or includes only a few transient bacteria originating from the oropharynx by a swallowing process or from the stomach by gastroesophageal reflux.⁹ Nevertheless, several pathogenic microorganisms, such as *Candida albicans*, *Cryptococcus* or Herpesvirus, can infect the esophagus.¹⁰ In the stomach, *Helicobacter pylori* has the ability to survive in the extremely acidic environment by secreting urease which converts urea to ammonia.¹¹ More than 50% of the world population is infected by this pathogenic bacterium¹² which can cause a range of gastric diseases such as peptic ulcers, gastric cancers, and mucosa-associated lymphoid tissue (MALT) lymphoma.^{13,14} Recently, non-*Helicobacter* species representing 3 main bacterial phyla (Firmicutes, Proteobacteria and Actinobacteria) were isolated from human gastric biopsies of patients with symptoms involving the gastroduodenal tract indicating that *H. pylori* is not the only bacterium that can be found in the acidic environment of the stomach.¹² Among these

CONTACT Jamuna Vadivelu ✉ jamuna@ummc.edu.my

Addendum to: Khosravi Y, Seow SW, Amoyo AA, Chiow KH, Tan TL, Wong WY, Poh QH, Sentosa IM, Bunte RM, Pettersson S, et al. *Helicobacter pylori* infection can affect energy modulating hormones and body weight in germ free mice. *Sci Rep* 2015; 5:8731; PMID: 25736205; <http://dx.doi.org/10.1038/srep08731>.

© 2016 Taylor & Francis Group, LLC

non-*Helicobacter* species, *Streptococcus* species (*S. mitis*, *S. parasanguinis* and *S. anginosus*) were most frequently isolated. These organisms are commonly found in the human oral cavity and were also found to be present in the lower gut.¹⁵ *In-vitro* experiments have shown that bile acids can transform *H. pylori* to the viable but non-culturable (VBNC) coccoidal form.¹⁶ Therefore, it is possible that in the bile-laden, anaerobic environment of the lower GI tract, *H. pylori* might exist in the VBNC state.¹⁷ The interaction between *H. pylori* and other microbiota of the GI (including *S. mitis*) can also lead to *H. pylori* converting to the VBNC form.¹⁸

***H. pylori* affecting gut hormones and energy homeostasis**

Leptin and ghrelin are 2 important hormones that influence on energy homeostasis in humans.¹⁹ The effect of leptin on energy homeostasis is opposite to that of ghrelin; leptin induces weight loss by suppression of food consumption, while ghrelin functions as an appetite-stimulatory signal.²⁰ *H. pylori*, which infects the human stomach and interacts with host tissues,²¹ may affect the regulation of hormones that are involved in energy homeostasis, such as ghrelin and leptin.¹⁹ However, effects of *H. pylori* infection on the expression of ghrelin and leptin in hosts are controversial.^{20,22,23} Tatsuguchi et al. demonstrated that ghrelin-positive cells in the gastric mucosa were significantly lower in *H. pylori*-infected adult patients than for healthy controls with an inverse correlation between ghrelin immunoreactivity and inflammation/activity grade.²² Likewise, Isomoto et al.²⁴ reported on the relationship between degree of *H. pylori*-associated gastritis and lower plasma ghrelin levels in-infected adult patients.²⁴ Furthermore, a recent study on comparison between *H. pylori*-infected and non-infected children demonstrated that both the serum ghrelin and leptin concentrations were significantly reduced in uninfected children.²⁵ Tatsuguchi et al. proposed that by inducing gastric atrophy, *H. pylori* damages ghrelin-producing endocrine cells localized in gastric mucosal layers and therefore alter their concentrations.²² Consistently, Francois et al. reported that circulating meal-associated ghrelin and leptin levels increase after successful *H. pylori* eradication collaborated by an increase in body mass index (BMI) in these subjects.²⁰ Host genetics, diet, lifestyle and other

confounding factors may influence the outcome of these studies using human subjects: as such, there is a need for *in vivo* studies conducted under controlled conditions.

In a study using a germ-free mouse model, *H. pylori*-induced carcinogenesis was shown to be delayed in the absence of the microbiota suggesting that microbiota plays an important role in *H. pylori*-associated pathogenesis.²⁶ More recently, Heijtz et al. highlighted the potential importance of gut microbiota for normal brain development during early stages of life in mice.⁷ In this study, mice were found to display increased motor activity and reduced anxiety in the absence of gut microbiota as a result of altered expression of genes involved in second messenger pathways and synaptic long-term potentiation in brain regions implicated in motor control and anxiety-like behavior.

To investigate the role of gut microbiota and *H. pylori* in energy homeostasis, the same C57BL/6 specific pathogen-free (SPF) and germ-free (GF) mouse models previously used by Heijtz et al.⁷ were adopted by Khosravi et al.²⁷ to which this addendum relates. Following from the study of Heijtz et al.⁷ Khosravi et al. explored the effects of gut microbiota and *H. pylori* on homeostasis of metabolic hormones of the gut-brain axis and circulating cytokines/ chemokines during early development.²⁷ In this study, 4 weeks old C57BL/6 SPF with normal gut microbiota and GF mice without normal gut microbiota were assigned into control (uninfected) and test (*H. pylori*-infected) groups. SPF and GF mice in the test group were infected with mice-adapted *H. pylori* strain 298 for 2 weeks, 2 months and 4 months. There is no simple answer on making age comparisons between mice and humans. It was estimated that a 1-month-old mouse is equivalent to a 12.5-year-old human adolescent while a mouse of 3–6 months old is comparable to a mature adult human of 20–30 y old.²⁸ Although mice are generally sexually mature by 35 days, maturational growth continues for most biological processes and structures until about 3 months of age. *H. pylori* infection is often acquired during childhood.²⁹ In developing countries, such as India, Saudi Arabia and Vietnam, approximately 80% of the population is infected by the age of 20.³⁰ Even in developed countries, such as South Korea, USA, France, Belgium and Finland, it was estimated that 10–12% of children aged 3–19 y old were infected.³⁰

Plasma leptin, insulin and total peptide YY (PYY) were elevated in *H. pylori*-infected SPF (SPFH) mice compared to non-infected SPF mice suggested that *H. pylori* infection altered the host metabolism. However, growth curves of SPF and SPFH mice remained the same. Similarly, acylated (active) ghrelin and PYY were elevated in GF mice infected with *H. pylori* (GFH) compared to non-infected GF mice. Ironically, GFH mice suffered significant weight loss relative to GF mice. Our results in mice confirmed that *H. pylori* and gut microbiota, singly and in combination, influence homeostasis of metabolic hormones of the gut-brain axis, which affects body weight. In contrast to study involving patients, which lifestyle, diet, environment and host genetic differences can be major confounding factors, mice study was carried out under controlled conditions.

Furthermore, plasma eotaxin-1, which plays a role in both inflammation and neurogenesis, was elevated in SPFH mice compared to SPF, GF and GFH mice. Increased eotaxin-1 level in blood plasma has been associated with aging in mice and humans.³¹ It has also been demonstrated that exposing young mice to eotaxin-1 or the blood plasma of older mice decreased their neurogenesis and cognitive performance in behavioral tasks, which are dependent on neurogenesis in the hippocampus.³¹ Interestingly, *H. pylori* infection alone in GFH mice suppressed circulating eotaxin-1 level. Therefore, it is possible that *H. pylori* exposure during early developmental stages will have long-term implication on brain development.

Metabolic gut hormones changes precede pathological changes

In addition, histology and immunohistochemistry (IHC) were performed on mice tissues from the stomach, small intestine and colon. Histopathological examination of hematoxylin and eosin (H&E) stained samples evaluated by a veterinary pathologist (RBM) revealed mildly-moderately dilated gastric crypts in 2 of the 5 16-weeks *H. pylori*-infected GF mice, which were also present in one of the 5 uninfected 16-weeks control GF mice. In the infected group, dilated crypts were seen in one animal in the fundic stomach and in the other in the pyloric stomach. In the control mice, dilated crypts were seen in the pyloric stomach. The dilated crypts did not contain any inflammatory cells.

In summary, these dilated gastric crypts are not uncommon in mice and are within normal limits.

H. pylori infection can affect neuronal expressions in the stomach of mice, which may explain the dyspepsia symptoms in *H. pylori*-infected patients. *H. pylori*-infected mice were shown to have enhanced neuronal expressions of substance P (SP), c-fos, vasoactive intestinal polypeptide (VIP) and calcitonin gene-related peptide expressions (CGRP) in their stomach.^{32,33} *H. pylori* cytotoxin-associated gene (*cag*) pathogenicity island, which is associated with cancer risk, *cag*, encodes for a secretion system that transports effectors into host cells leading to aberrant activation of β -catenin.³⁴ β -catenin affects oncogenesis in conjunction with peroxisome proliferator-activated receptor (PPAR) δ .³⁵ The expression of 6 biomarkers (SP, c-fos, VIP, CGRP, PPAR δ and β -catenin) in mice gastric tissue samples were assessed by IHC.³⁶ Heat-induced epitope retrieval in 10 mM citrate buffer (pH 6.0) was used on paraffin-embedded sections in this study.³⁷ Goat polyclonal anti-SP (NC-18; sc-9758), rabbit polyclonal anti-c-fos (sc-52), rabbit polyclonal anti-VIP (H-95; sc-20727), rabbit polyclonal anti-CGRP (H-48; sc-28920), rabbit polyclonal anti-PPAR δ (H-74; sc-7197) and rabbit polyclonal anti- β -catenin (H-102; sc-7199) at 1:50 dilutions were used as primary antibodies. Donkey anti-goat IgG, F(ab')₂-HRP (sc-3851) and goat anti-rabbit IgG F(ab')₂-HRP (sc-3837) at 1:100 dilutions were used as secondary antibodies. Primary and secondary antibodies used were from Santa Cruz Biotechnology, Inc.. Normal donkey serum (Santa Cruz) was used for blocking. Labeled StreptAvidin Biotin (LSAB) kit (DAKO) was used for detection. Secondary antibody only control was performed using the same procedure, with PBS substituting for primary antibodies. For immunostaining of SP, c-fos, VIP and CGRP-expressing neurons in the mouse stomach, cells with cytoplasm or nuclei showing brown-yellow to brown-black were considered positive.^{32,33} As for PPAR δ , epithelial cells were evaluated in the epithelium of antral mucosa.³⁵ For β -catenin immunostaining, epithelial cells from well-oriented representative gastric glands were scored.³⁴ The intensity of positive staining was categorized as follow: 0, negative; 1, mild (brown-yellow); 2, moderate (brown); 3, severe (brown-black). For semi-quantitative analysis of each sample, 100 cells were counted by a single blinded observer and the percentage of positive cells was multiplied by the intensity score.

Comparing all 6 biomarkers between 16-weeks SPF and GF mice, more cells were stained positive in GF mice for c-fos, VIP, CGRP, PPAR δ and β -catenin, regardless of *H. pylori* infection. VIP and β -catenin also appeared more abundant in SPFH and GFH mice compared to SPF and GF mice respectively. However, due to the small number of animals in this study and heterogeneity of their distribution in mice stomach, the differences in all 6 biomarkers did not achieved statistical significant. These results are in contrast with multiple studies,^{32,33,34} in which expression of these 6 proteins were found to be up-regulated post-infection with *H. pylori* in mice models. This discrepancy may be due to the genetic diversity of *H. pylori* strains used and the duration of infection in mice. Nevertheless, data from this study also showed that *H. pylori*-induced changes in metabolic hormones of the gut-brain axis in mice preceded any observable histopathological changes in the mice stomach. Thus, it is unlikely that *H. pylori*-induced damage to hormone-producing endocrine cells in the gastric mucosal layers were responsible for the augmentation of these metabolic hormones during early stages of *H. pylori* infection. However, that does not rule out the possibility that gastric mucosal damage or inflammation induced by *H. pylori* during later stages of infection may further augment metabolic hormonal balance and energy homeostasis.

Conclusion

This study demonstrated that *H. pylori* and gut microbiota, singly and in combination, influence homeostasis of metabolic hormones of the gut-brain axis (ghrelin, leptin, insulin and peptide YY), which affects body weight, under controlled conditions in mice. Furthermore, the augmentation of gut hormones by *H. pylori* precedes and is independent of histopathological changes associated with infection by the bacterium during early stages of *H. pylori* infection. Further investigations are necessary to ascertain the long-term impact of the augmented gut hormone profile on health and disease.

Abbreviations

BMI	Body mass index
CGRP	Calcitonin gene-related peptide
GF	Germ-free
GI	Gastrointestinal
<i>H. pylori</i>	<i>Helicobacter pylori</i>
HIER	Heat induced epitope retrieval

IHC	Immunohistochemistry
LSAB	Substance P, C-fos, Labeled streptavidin biotin
PIER	proteolytic induced epitope retrieval
PPAR β	β -catenin, peroxisome proliferator-activated receptor β
SPF	Specific pathogen-free
VBNC	Viable but non-culturable
VIP	Vasoactive intestinal peptide.

Disclosure of potential conflicts of interest

No potential conflict of interest was disclosed.

Funding

This study was supported by (1) University of Malaya-Ministry of Education (UM-MoE) High Impact Research (HIR) Grant UM.C/625/1/HIR/MoE/CHAN/02 (Account No. H-50001-A000013) to J.V., (2) Singapore Polytechnic Grant (GL Account: 11-27801-45-3341) to K.H.C., and (3) grants from Vetenskapsrådet, EU-project TORNADO, Mérieux Institute, Singapore Millennium Foundation, LKC School of Medicine NTU and SCELSE, Microbiome Center at NTU to S.P.

References

- Warrell DA. Oxford textbook of medicine: Sections 18-33. Oxford University Press. 2005; 511-ISBN 978-0-19-856978-7
- Kapoor KK. Large Intestine Anatomy. In Gest, Thomas R. Medscape. WebMD LLC. Retrieved 2013-08-20
- Maccaferri S, Biagi E, Brigidi P. Metagenomics. Key to human gut microbiota. Dig Dis 2011; 29:525-30; PMID:22179207; <http://dx.doi.org/10.1159/000332966>
- Claesson MJ, Jeffery IB, Conde S, Power SE, O'Connor EM, Cusack S, Harris HM, Coakley M, Lakshminarayanan B, O'Sullivan O, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012; 488:178-84; PMID:22797518; <http://dx.doi.org/10.1038/nature11319>
- Koren O, Goodrich JK, Cullender TC, Spor A, Laitinen K, Bäckhed HK, Gonzalez A, Werner JJ, Angenent LT, Knight R, et al. Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell 2012; 150:470-80; PMID:22863002; <http://dx.doi.org/10.1016/j.cell.2012.07.008>
- Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature 2012; 489:220-30; PMID:22972295; <http://dx.doi.org/10.1038/nature11550>
- Heijtz RD, Wang S, Anuar F, Qian Y, Björkholm B, Samuelsson A, Hibberd ML, Forssberg H, Pettersson S. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A 2011; 108:3047-52; PMID:21282636; <http://dx.doi.org/10.1073/pnas.1010529108>
- Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev 2010; 90:859-904; PMID:20664075; <http://dx.doi.org/10.1152/physrev.00045.2009>

9. Gagliardi D, Makihara S, Corsi PR, Viana Ade T, Wiczler MV, Nakakubo S, Mimica LM. Microbial flora of the normal esophagus. *Dis Esophagus* 1998; 11:248-50; PMID:10071807
10. Cassone A, Cauda R. Candida and candidiasis in HIV-infected patients: where commensalism, opportunistic behavior and frank pathogenicity lose their borders. *AIDS* 2012; 26:1457-72; PMID:22472853; <http://dx.doi.org/10.1097/QAD.0b013e3283536ba8>
11. Weeks DL, Eskandari S, Scott DR, Sachs G. A H⁺-gated urea channel: the link between *Helicobacter pylori* urease and gastric colonization. *Science* 2000; 287:482-5; PMID:10642549; <http://dx.doi.org/10.1126/science.287.5452.482>
12. Khosravi Y, Dieye Y, Poh BH, Ng CG, Loke MF, Goh KL, Vadivelu J. Culturable bacterial microbiota of the stomach of *Helicobacter pylori* positive and negative gastric disease patients. *Scientific World J* 2014; 2014:610421
13. Correa P, Houghton J. Carcinogenesis of *Helicobacter pylori*. *Gastroenterology* 2007; 133:659-72; PMID:17681184; <http://dx.doi.org/10.1053/j.gastro.2007.06.026>
14. Wang AY, Peura DA. The prevalence and incidence of *Helicobacter pylori*-associated peptic ulcer disease and upper gastrointestinal bleeding throughout the world. *Gastrointest Endosc Clin N Am* 2011; 21:613-35; PMID:21944414; <http://dx.doi.org/10.1016/j.giec.2011.07.011>
15. Van den Bogert B, Boekhorst J, Herrmann R, Smid EJ, Zoetendal EG, Kleerebezem M. Comparative genomics analysis of *Streptococcus* isolates from the human small intestine reveals their adaptation to a highly dynamic ecosystem. *PLoS One* 2013; 8:e83418; PMID:24386196; <http://dx.doi.org/10.1371/journal.pone.0083418>
16. Hänninen ML. Sensitivity of *Helicobacter pylori* to different bile salts. *Eur J Clin Microbiol Infect Dis* 1991; 10:515-8; <http://dx.doi.org/10.1007/BF01963941>
17. Owen RJ. *Helicobacter*-species classification and identification. *Br Med Bull* 1998; 54:17-30; PMID:9604427; <http://dx.doi.org/10.1093/oxfordjournals.bmb.a011667>
18. Catrenich CE, Makin KM. Characterization of the morphologic conversion of *Helicobacter pylori* from bacillary to coccoid forms. *Scand J Gastroenterol Suppl* 1991; 181:58-64; PMID:1866596; <http://dx.doi.org/10.3109/00365529109093209>
19. Roper J, Francois F, Shue PL, Mourad MS, Pei Z, Olivares de Perez AZ, Perez-Perez GI, Tseng CH, Blaser MJ. Leptin and ghrelin in relation to *Helicobacter pylori* status in adult males. *J Clin Endocrinol Metab* 2008; 93:2350-7; PMID:18397989; <http://dx.doi.org/10.1210/jc.2007-2057>
20. Francois F, Roper J, Joseph N, Pei Z, Chhada A, Shak JR, de Perez AZ, Perez-Perez GI, Blaser MJ. The effect of *H. pylori* eradication on meal-associated changes in plasma ghrelin and leptin. *BMC Gastroenterol* 2011; 11:37; PMID:21489301; <http://dx.doi.org/10.1186/1471-230X-11-37>
21. Atherton JC, Blaser MJ. Coadaptation of *Helicobacter pylori* and humans: ancient history, modern implications. *J Clin Invest* 2009; 119:2475-87; PMID:19729845; <http://dx.doi.org/10.1172/JCI38605>
22. Tatsuguchi A, Miyake K, Gudis K, Futagami S, Tsukui T, Wada K, Kishida T, Fukuda Y, Sugisaki Y, Sakamoto C. Effect of *Helicobacter pylori* infection on ghrelin expression in human gastric mucosa. *Am J Gastroenterol* 2004; 99:2121-7; PMID:15554990; <http://dx.doi.org/10.1111/j.1572-0241.2004.30291.x>
23. Nwokolo CU, Freshwater DA, O'Hare P, Randeve HS. Plasma ghrelin following cure of *Helicobacter pylori*. *Gut* 2003; 52:637-40; PMID:12692045; <http://dx.doi.org/10.1136/gut.52.5.637>
24. Isomoto H, Nakazato M, Ueno H, Date Y, Nishi Y, Mukae H, Mizuta Y, Ohtsuru A, Yamashita S, Kohno S. Low plasma ghrelin levels in patients with *Helicobacter pylori*-associated gastritis. *Am J Med* 2004; 117:429-432; PMID:15380500; <http://dx.doi.org/10.1016/j.amjmed.2004.01.030>
25. Plonka M, Bielanski W, Konturek SJ, Targosz A, Sliwowski Z, Dobrzanska M, Kaminska A, Sito E, Konturek PC, Brzozowski T. *Helicobacter pylori* infection and serum gastrin, ghrelin and leptin in children of Polish shepherds. *Dig Liver Dis* 2006; 38:91-7; PMID:16293448
26. Lofgren JL, Whary MT, Ge Z, Muthupalani S, Taylor NS, Mobley M, Potter A, Varro A, Eibach D, Suerbaum S, et al. Lack of commensal flora in *Helicobacter pylori*-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. *Gastroenterology* 2011; 140:210-20; PMID:20950613; <http://dx.doi.org/10.1053/j.gastro.2010.09.048>
27. Khosravi Y, Seow SW, Amoyo AA, Chiow KH, Tan TL, Wong WY, Poh QH, Sentosa IM, Bunte RM, Pettersson S, et al. *Helicobacter pylori* infection can affect energy modulating hormones and body weight in germ free mice. *Sci Rep* 2015; 5:8731; PMID:25736205; <http://dx.doi.org/10.1038/srep08731>
28. Flurkey K, Curren JM, Harrison DE. 2007. The Mouse in Aging Research. In *The Mouse in Biomedical Research* 2nd Edition. Fox JG, et al, editors. American College Laboratory Animal Medicine (Elsevier), Burlington, MA. pp:637-72
29. Mitchell HM, Li YY, Hu PJ, Liu Q, Chen M, Du GG, Wang ZJ, Lee A, Hazell SL. Epidemiology of *Helicobacter pylori* in southern China: identification of early childhood as the critical period for acquisition. *J Infect Dis*. 1992; 166:149-53; PMID:1607687; <http://dx.doi.org/10.1093/infdis/166.1.149>
30. Mégraud F, Brassens-Rabbé MP, Denis F, Belbourni A, Hoa DQ. Seroepidemiology of *Campylobacter pylori* infection in various populations. *J Clin Microbiol* 1989; 27:1870-3; PMID:2549098
31. Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, Stan TM, Fainberg N, Ding Z, Eggel A, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. *Nature* 2011; 477:90-4; PMID:21886162; <http://dx.doi.org/10.1038/nature10357>
32. Li XB, Chen HM, Lu H, Zheng Q, Chen XY, Peng YS, Ge ZZ, Liu WZ. Role of *Helicobacter pylori* infection on neuronal expression in the stomach and spinal cord of a murine model. *J Dig Dis* 2009; 10:286-92; PMID:19906107; <http://dx.doi.org/10.1111/j.1751-2980.2009.00397.x>

33. Berćík P, De giorgio R, Blennerhassett P, Verdú EF, Barbara G, Collins SM. Immune-mediated neural dysfunction in a murine model of chronic *Helicobacter pylori* infection. *Gastroenterology* 2002; 123:1205-15; <http://dx.doi.org/10.1053/gast.2002.36024>
34. Franco AT, Israel DA, Washington MK, Krishna U, Fox JG, Rogers AB, Neish AS, Collier-Hyams L, Perez-Perez GI, Hatakeyama M, et al. Activation of β -catenin by carcinogenic *Helicobacter pylori*. *Proc Natl Acad Sci U S A* 2005; 102:10646-51; PMID:16027366; <http://dx.doi.org/10.1073/pnas.0504927102>
35. Nagy TA, Wroblewski LE, Wang D, Piazuelo MB, Delgado A, Romero-Gallo J, Noto J, Israel DA, Ogden Sr, Correa P, et al. β -Catenin and p120 mediate PPAR delta-dependent proliferation induced by *Helicobacter pylori* in human and rodent epithelia. *Gastroenterology* 2011; 141:553-64; PMID: 21704622; <http://dx.doi.org/10.1053/j.gastro.2011.05.004>
36. Anon. *Dako Handbook Immunohistochemical Staining Methods* 3rd edition (online). Dako 2001
37. Anon. *Introduction to Immunohistochemistry: Antigen Retrieval*. Available: http://www.ihcworld.com/_intro/antigen-retrieval.htm 2011